The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer
The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer
复制标题
使用碱性和酸性磷酸酶的血清同工酶作为前列腺癌肿瘤负荷的可能定量标记物
DOI：
--
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
T. Chu
中科院分区：
文献类型：
--
作者：
C. Killian;F. Vargas;E. Pontes;S. Beckley;N. Slack;G. Murphy;T. Chu
纵向比较了98例转移性前列腺癌患者的肿瘤负荷与碱性磷酸酶、总酸性磷酸酶和前列腺特异性酸性磷酸酶的骨（BAP）和肝同工酶（ALP）活性。通过比较酶与1）治疗反应和放射性核素骨扫描估计转移; 2）基于放射学证据的转移，提出了这些酶标志物与肿瘤质量之间的定量相关性。此外，明显广泛的治疗前骨肿瘤负荷预测BAP活性升高，这也是先前报道的预后不良的提示。与AcP相比，PAP升高可能先于某些患者的临床疾病进展。本报告中提供的数据表明，这些酶的水平与肿瘤累及的程度相比很好，因此可能被认为适合作为骨和肝转移的辅助甚至定量生化标志物。
The tumor burden of 98 patients with metastatic prostatic cancer was compared longitudinally with the activities of bone (BAP) and liver isoenzymes (LAP) of alkaline phosphatase, total acid phosphatase (AcP), and prostate‐specific acid phosphatase (PAP). A quantitative association between these enzyme markers and the tumor mass was suggested by comparing the enzymes with 1) both the treatment response and the estimation of metastasis by radionuclide bone scanning; 2) metastasis based upon radiographic evidence. In addition, an apparent extensive pretreatment bone tumor load was predictive for an elevated BAP activity, which was also a suggestive poor prognosis as previously reported. An elevation of PAP, in contrast to AcP, may precede the clinical disease progression in some patients. Data presented in this report have indicated that the levels of these enzymes compared well with the extent of tumor involvement and therefore may be considered suitable as adjuvant and even quantitative biochemical markers of bone and liver metastasis.